Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs
By Tom Zanki · January 27, 2025, 7:18 PM EST
Obesity-focused drug developer Metsera launched plans on Monday for an estimated $275 million initial public offering, joined by kidney-disease focused Maze Therapeutics, both of which plan to tap the markets this...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login